Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 10/20 | 0.52 |
| ▸ | GRM5 | P41594 | 9/20 | 0.52 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.52 |
| ▸ | CDK7 | P50613 | 1/20 | 0.50 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.50 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | MAP3K5 | Q99683 | 4/20 | 0.44 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5662827 | 0.85 | NAMPT (0.42) | CDK7CDK13CDK12NAMPT | |
| SCHEMBL30308912 | 0.85 | GRM1 (0.64) | GRM1GRM5PDK4NAMPTJAK1 | |
| SCHEMBL23362181 | 0.81 | GRM1 (0.59) | GRM1GRM5PDK4NAMPTJAK1 | |
| SCHEMBL29664333 | 0.81 | GRM1 (0.59) | GRM1GRM5PDK4NAMPTJAK1 | |
| SCHEMBL16544582 | 0.81 | GRM5 (0.59) | GRM1GRM5PDK4NAMPT | |
| SCHEMBL2878306 | 0.80 | GRM1 (0.60) | GRM1GRM5PDK4NAMPTJAK1 | |
| SCHEMBL5337565 | 0.80 | GRM1 (0.58) | GRM1GRM5PDK4NAMPTJAK1 | |
| SCHEMBL5337540 | 0.80 | GRM1 (0.58) | GRM1GRM5PDK4NAMPTJAK1 | |
| SCHEMBL23873484 | 0.80 | GRM1 (0.58) | GRM1GRM5PDK4NAMPTJAK1 | |
| SCHEMBL29826464 | 0.80 | GRM1 (0.60) | GRM1GRM5PDK4NAMPTJAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MARZABADI MOHAMMAD R | 2007-02-22 | — | — | US | disclosed |
| US-7067534-B1 | Substituted anilinic piperidines as MCH selective antagonists | H. LUNDBECK A/S (DK) | 2006-06-27 | — | — | US | disclosed |
| US-6727264-B1 | MELANIN CONCENTRATING HORMONE-1 RECEPTOR ANTAGONISTS; SLEEP, EATING, SEXUAL DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MCHR1, MCHR2, MC1R | GRM1 288/4885GRM5 609/4885PDK4 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.